Prothena Reports Q4 & FY 2025 Results, Initiates Two Phase 3 Trials, and Provides 2026 Financial Guidance

summarizeSummary

Prothena reported Q4 and full year 2025 financial results, highlighted by significant pipeline progress with two Phase 3 trial initiations and a strong cash runway, despite a substantial year-over-year revenue decline and increased full-year net loss.

check_boxKey Events

• Mixed Q4 and Full Year 2025 Financial Results

  Prothena reported a net loss of $21.6 million for Q4 2025 (improved from Q4 2024) but a full year net loss of $244.1 million (worsened from FY 2024), with total revenue for FY 2025 significantly down to $9.7 million from $135.2 million in FY 2024. The full-year loss included $30.1 million in restructuring charges and a $43.2 million non-cash income tax expense.

• Two Phase 3 Clinical Trials Initiated by Partners

  Roche initiated the Phase 3 PARAISO trial for prasinezumab in early-stage Parkinson's disease, and Novo Nordisk initiated the Phase 3 CLEOPATTRA trial for coramitug in ATTR amyloidosis with cardiomyopathy, both with primary completion expected in 2029.

• Strong 2026 Financial Guidance and Cash Position

  The company expects net cash used in operating and investing activities to be $50 to $55 million for 2026, projecting to end the year with approximately $255 million in cash. This guidance excludes potential clinical milestone payments of up to $105 million from strategic partners.

• Share Redemption Program Approved by Shareholders

  Shareholders approved a capital reduction to create distributable reserves, providing the Board of Directors with flexibility to potentially return capital to shareholders via a share redemption program in 2026.

auto_awesomeAnalysis

Prothena reported mixed financial results for Q4 and full year 2025, with a significant year-over-year decline in revenue and an increased net loss for the full year, partly due to restructuring charges and a non-cash income tax expense. However, the company announced substantial pipeline advancements, including the initiation of two pivotal Phase 3 clinical trials for prasinezumab (Parkinson's disease) and coramitug (ATTR amyloidosis with cardiomyopathy) by its strategic partners. Additionally, Prothena provided 2026 financial guidance projecting a manageable net cash burn and a strong cash balance, which does not include potential clinical milestone payments of up to $105 million. The approval for a potential share redemption program in 2026 also offers flexibility for capital return to shareholders. For a clinical-stage biotechnology company, the advancement of multiple programs into late-stage trials and a solid cash runway are critical positive indicators, balancing out the weaker historical financial performance.